PortfoliosLab logoPortfoliosLab logo
ENVA vs. CORT
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Performance

ENVA vs. CORT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Enova International, Inc. (ENVA) and Corcept Therapeutics Incorporated (CORT). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

ENVA vs. CORT - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
ENVA
Enova International, Inc.
-12.92%63.95%73.19%44.28%-6.32%65.36%2.95%23.64%28.03%21.12%
CORT
Corcept Therapeutics Incorporated
20.63%-30.94%55.14%59.92%2.58%-24.31%116.20%-9.43%-26.02%148.76%

Fundamentals

EPS

ENVA:

$11.58

CORT:

$0.88

PE Ratio

ENVA:

11.82

CORT:

47.88

PEG Ratio

ENVA:

0.64

CORT:

23.85

PS Ratio

ENVA:

1.16

CORT:

6.79

Total Revenue (TTM)

ENVA:

$3.15B

CORT:

$741.17M

Gross Profit (TTM)

ENVA:

$1.58B

CORT:

$727.78M

EBITDA (TTM)

ENVA:

$529.82M

CORT:

$72.46M

Returns By Period

In the year-to-date period, ENVA achieves a -12.92% return, which is significantly lower than CORT's 20.63% return. Over the past 10 years, ENVA has outperformed CORT with an annualized return of 36.63%, while CORT has yielded a comparatively lower 24.43% annualized return.


ENVA

1D
0.78%
1M
-3.32%
YTD
-12.92%
6M
21.99%
1Y
37.00%
3Y*
45.51%
5Y*
30.56%
10Y*
36.63%

CORT

1D
4.14%
1M
16.71%
YTD
20.63%
6M
-50.17%
1Y
-54.33%
3Y*
24.68%
5Y*
11.44%
10Y*
24.43%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

ENVA vs. CORT — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ENVA
ENVA Risk / Return Rank: 6969
Overall Rank
ENVA Sharpe Ratio Rank: 7070
Sharpe Ratio Rank
ENVA Sortino Ratio Rank: 6565
Sortino Ratio Rank
ENVA Omega Ratio Rank: 6464
Omega Ratio Rank
ENVA Calmar Ratio Rank: 7373
Calmar Ratio Rank
ENVA Martin Ratio Rank: 7373
Martin Ratio Rank

CORT
CORT Risk / Return Rank: 99
Overall Rank
CORT Sharpe Ratio Rank: 1111
Sharpe Ratio Rank
CORT Sortino Ratio Rank: 1616
Sortino Ratio Rank
CORT Omega Ratio Rank: 1212
Omega Ratio Rank
CORT Calmar Ratio Rank: 33
Calmar Ratio Rank
CORT Martin Ratio Rank: 33
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ENVA vs. CORT - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Enova International, Inc. (ENVA) and Corcept Therapeutics Incorporated (CORT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


ENVACORTDifference

Sharpe ratio

Return per unit of total volatility

0.88

-0.71

+1.59

Sortino ratio

Return per unit of downside risk

1.42

-0.64

+2.06

Omega ratio

Gain probability vs. loss probability

1.19

0.88

+0.31

Calmar ratio

Return relative to maximum drawdown

1.69

-0.97

+2.66

Martin ratio

Return relative to average drawdown

4.20

-1.84

+6.05

ENVA vs. CORT - Sharpe Ratio Comparison

The current ENVA Sharpe Ratio is 0.88, which is higher than the CORT Sharpe Ratio of -0.71. The chart below compares the historical Sharpe Ratios of ENVA and CORT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading graphics...

Sharpe Ratios by Period


ENVACORTDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.88

-0.71

+1.59

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.76

0.16

+0.61

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.73

0.37

+0.37

Sharpe Ratio (All Time)

Calculated using the full available price history

0.30

0.08

+0.22

Correlation

The correlation between ENVA and CORT is 0.22, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Dividends

ENVA vs. CORT - Dividend Comparison

Neither ENVA nor CORT has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

ENVA vs. CORT - Drawdown Comparison

The maximum ENVA drawdown since its inception was -81.56%, smaller than the maximum CORT drawdown of -94.28%. Use the drawdown chart below to compare losses from any high point for ENVA and CORT.


Loading graphics...

Drawdown Indicators


ENVACORTDifference

Max Drawdown

Largest peak-to-trough decline

-81.56%

-94.28%

+12.72%

Max Drawdown (1Y)

Largest decline over 1 year

-24.75%

-64.40%

+39.65%

Max Drawdown (5Y)

Largest decline over 5 years

-42.84%

-71.85%

+29.01%

Max Drawdown (10Y)

Largest decline over 10 years

-77.57%

-71.85%

-5.72%

Current Drawdown

Current decline from peak

-20.58%

-63.25%

+42.67%

Average Drawdown

Average peak-to-trough decline

-29.97%

-53.45%

+23.48%

Ulcer Index

Depth and duration of drawdowns from previous peaks

9.94%

34.29%

-24.35%

Volatility

ENVA vs. CORT - Volatility Comparison

The current volatility for Enova International, Inc. (ENVA) is 8.54%, while Corcept Therapeutics Incorporated (CORT) has a volatility of 22.09%. This indicates that ENVA experiences smaller price fluctuations and is considered to be less risky than CORT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading graphics...

Volatility by Period


ENVACORTDifference

Volatility (1M)

Calculated over the trailing 1-month period

8.54%

22.09%

-13.55%

Volatility (6M)

Calculated over the trailing 6-month period

29.02%

85.39%

-56.37%

Volatility (1Y)

Calculated over the trailing 1-year period

42.20%

79.00%

-36.80%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

40.28%

73.98%

-33.70%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

50.08%

67.09%

-17.01%

Financials

ENVA vs. CORT - Financials Comparison

This section allows you to compare key financial metrics between Enova International, Inc. and Corcept Therapeutics Incorporated. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00200.00M400.00M600.00M800.00MAprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober
839.39M
207.64M
(ENVA) Total Revenue
(CORT) Total Revenue
Values in USD except per share items

ENVA vs. CORT - Profitability Comparison

The chart below illustrates the profitability comparison between Enova International, Inc. and Corcept Therapeutics Incorporated over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

50.0%60.0%70.0%80.0%90.0%100.0%AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober
59.8%
97.8%
Portfolio components
ENVA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Enova International, Inc. reported a gross profit of 501.89M and revenue of 839.39M. Therefore, the gross margin over that period was 59.8%.

CORT - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Corcept Therapeutics Incorporated reported a gross profit of 203.04M and revenue of 207.64M. Therefore, the gross margin over that period was 97.8%.

ENVA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Enova International, Inc. reported an operating income of 186.65M and revenue of 839.39M, resulting in an operating margin of 22.2%.

CORT - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Corcept Therapeutics Incorporated reported an operating income of 10.22M and revenue of 207.64M, resulting in an operating margin of 4.9%.

ENVA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Enova International, Inc. reported a net income of 78.98M and revenue of 839.39M, resulting in a net margin of 9.4%.

CORT - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Corcept Therapeutics Incorporated reported a net income of 19.36M and revenue of 207.64M, resulting in a net margin of 9.3%.